Navigation Links
Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy
Date:8/21/2014

MISSISSAUGA, ON, Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to support the Canadian Epilepsy Alliance (CEA) in the introduction of the first-of-its-kind comic book available in Canada. The comic book, an innovative educational tool, has been designed specifically to educate children and their parents about epilepsy, the most common neurological disorder in Canada affecting more than 300,000 Canadians. Eisai is guided by a corporate philosophy known as human health care (hhc), in which the patient is central – there was a need within the epilepsy community to help facilitate greater understanding of the disorder for future generations and this certainly aligns with hhc.

"The CEA is always looking for innovative ways to educate Canadians about epilepsy," says Oliver Technow, President and General Manager, Eisai Limited. "Their latest initiative, the MediKidz comic book, takes a unique approach to educating children in a format that resonates, we also know that this will help to inform teachers and parents who may not be familiar with the most common neurological condition in Canada."

Authored by doctors and medical writers, the book's content addresses the mechanics, diagnosis, and treatment of epilepsy and is peer-reviewed by leading medical professionals and endorsed by the Canadian epilepsy community. The MediKidz Explain Epilepsy will be made available through the Canadian Epilepsy Alliance across the country.

About Eisai Limited

Eisai established the Canadian pharmaceutical company Eisai Limited in 2010. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited is based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America. For more information about Eisai in Canada, please visit www.eisai.ca

About Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.


'/>"/>
SOURCE Eisai Limited
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
2. Eisai Oncology to Present New Research on Eribulin and NEPA at 36th Annual San Antonio Breast Cancer Symposium
3. Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs
4. Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
5. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
6. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
7. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
8. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
9. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
10. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
11. FDA Grants Orphan Drug Status To Eisais Lenvatinib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):